PMID- 15030120
OWN - NLM
STAT- MEDLINE
DCOM- 20040707
LR  - 20220716
IS  - 0043-5325 (Print)
IS  - 0043-5325 (Linking)
VI  - 116
IP  - 1-2
DP  - 2004 Jan 31
TI  - Prognostic markers in breast cancer: the reliability of HER2/neu status in core 
      needle biopsy of 325 patients with primary breast cancer.
PG  - 26-31
AB  - INTRODUCTION: The assessment of HER2/neu overexpression in tissue provides 
      information about one of the most relevant prognostic and predictive markers in 
      breast cancer: overexpression of HER2/neu is associated with worse prognosis in 
      primary breast cancer. Since core needle biopsy is increasingly used for the 
      diagnosis of breast cancer, the purpose of this study was to assess the 
      reliability of HER2/neu evaluation using this technique in patients with primary 
      breast cancer. PATIENTS AND METHODS: We investigated the accuracy of 
      immunohistochemical assessment of HER2/neu in core needle biopsies compared with 
      surgically obtained specimens in 325 patients with primary breast cancer. In 
      patients strongly positive for HER2/neu, additional fluorescence in situ 
      hybridization (FISH) analysis of needle biopsies was performed. RESULTS: Using 
      immunohistochemistry alone, accuracy of HER2/neu assessment in core biopsies in 
      relation to surgically removed specimens was 92% and increased to 96% with 
      additional FISH analysis (weighted Kappa coefficient: 0.86). DISCUSSION: As 
      proven with this large series of patients, the assessment of HER2/neu status by 
      core needle biopsy in breast cancer is accurate. Notwithstanding, in order to 
      minimize the number of false-positive results, strongly positive core needle 
      biopsies identified using immunohistochemistry should be confirmed by FISH 
      analysis.
FAU - Taucher, Susanne
AU  - Taucher S
AD  - Department of Surgery, Vienna University Medical School, Vienna, Austria. 
      susanne.taucher@univie.ac.at
FAU - Rudas, Margaretha
AU  - Rudas M
FAU - Mader, Robert M
AU  - Mader RM
FAU - Gnant, Michael
AU  - Gnant M
FAU - Dubsky, Peter
AU  - Dubsky P
FAU - Roka, Sebastian
AU  - Roka S
FAU - Bachleitner, Thomas
AU  - Bachleitner T
FAU - Kandioler, Daniela
AU  - Kandioler D
FAU - Steger, Gunther
AU  - Steger G
FAU - Mittlbock, Martina
AU  - Mittlbock M
FAU - Jakesz, Raimund
AU  - Jakesz R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Austria
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Genetic Markers)
RN  - 0 (Reagent Kits, Diagnostic)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
CIN - Wien Klin Wochenschr. 2004 Jan 31;116(1-2):3-5. PMID: 15030116
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Biopsy, Needle
MH  - Breast/pathology
MH  - Breast Neoplasms/drug therapy/*genetics/pathology/surgery
MH  - Carcinoma, Ductal/drug therapy/*genetics/pathology/surgery
MH  - Carcinoma, Lobular/drug therapy/*genetics/pathology/surgery
MH  - Chromosomes, Human, Pair 17
MH  - Combined Modality Therapy
MH  - Female
MH  - Genetic Markers/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Reagent Kits, Diagnostic
MH  - Receptor, ErbB-2/*genetics
MH  - Trastuzumab
EDAT- 2004/03/20 05:00
MHDA- 2004/07/09 05:00
CRDT- 2004/03/20 05:00
PHST- 2004/03/20 05:00 [pubmed]
PHST- 2004/07/09 05:00 [medline]
PHST- 2004/03/20 05:00 [entrez]
AID - 10.1007/BF03040420 [doi]
PST - ppublish
SO  - Wien Klin Wochenschr. 2004 Jan 31;116(1-2):26-31. doi: 10.1007/BF03040420.